Eversept Partners LP boosted its stake in TG Therapeutics Inc (NASDAQ:TGTX) by 18.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 883,501 shares of the biopharmaceutical company’s stock after purchasing an additional 134,907 shares during the period. TG Therapeutics comprises 2.2% of Eversept Partners LP’s investment portfolio, making the stock its 12th largest position. Eversept Partners LP owned 1.00% of TG Therapeutics worth $7,642,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors also recently made changes to their positions in the business. Tower Research Capital LLC TRC purchased a new position in TG Therapeutics in the 2nd quarter worth approximately $98,000. BlackRock Inc. increased its stake in shares of TG Therapeutics by 19.5% during the second quarter. BlackRock Inc. now owns 5,304,463 shares of the biopharmaceutical company’s stock valued at $45,883,000 after buying an additional 866,572 shares during the period. Parametric Portfolio Associates LLC increased its stake in shares of TG Therapeutics by 45.4% during the second quarter. Parametric Portfolio Associates LLC now owns 21,152 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 6,609 shares during the period. Athanor Capital LP purchased a new position in shares of TG Therapeutics during the second quarter valued at approximately $198,000. Finally, Sofinnova Investments Inc. increased its stake in shares of TG Therapeutics by 258.5% during the second quarter. Sofinnova Investments Inc. now owns 1,261,384 shares of the biopharmaceutical company’s stock valued at $10,911,000 after buying an additional 909,573 shares during the period. 52.96% of the stock is currently owned by institutional investors and hedge funds.
In other TG Therapeutics news, CFO Sean A. Power sold 17,654 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $8.47, for a total value of $149,529.38. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Michael S. Weiss bought 50,000 shares of the stock in a transaction on Wednesday, June 26th. The stock was purchased at an average cost of $7.04 per share, for a total transaction of $352,000.00. The disclosure for this purchase can be found here. Corporate insiders own 14.20% of the company’s stock.
TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.01. The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative return on equity of 496.99% and a negative net margin of 99,488.13%. As a group, equities analysts predict that TG Therapeutics Inc will post -1.52 earnings per share for the current fiscal year.
Several equities analysts have recently issued reports on the company. B. Riley reissued a “buy” rating on shares of TG Therapeutics in a research note on Tuesday, June 11th. Zacks Investment Research raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 15th. BidaskClub cut TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 22nd. Finally, ValuEngine raised TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $14.07.
TG Therapeutics Profile
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.
Recommended Story: How is a buy-side analyst different from a sell-side analyst?
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.